DiaMedica Retains Leading Investor Relations Firm
June 02 2009 - 9:10AM
Marketwired
DiaMedica Inc. (TSX VENTURE: DMA), a biotechnology company
developing novel treatments for various stages of type 2 diabetes,
is pleased to announce that it has retained The Equicom Group Inc.
to provide DiaMedica with strategic investor relations and
communication services.
Equicom provides investor relations to public companies in
Canada and specializes in the development and execution of
tailored, strategic investor communications programs. Equicom is a
wholly-owned subsidiary of the TMX Group Inc. and is headquartered
in Toronto with offices in Montreal and Calgary. The principals and
representatives of Equicom hold no common shares of DiaMedica
either directly or indirectly.
Pursuant to the Agreement, Equicom will be responsible for
designing and implementing a customized investor relations strategy
that clearly identifies DiaMedica's market position and potential.
Equicom will also provide the Company with a number of other
services including: ongoing capital markets counsel; preparation of
investor relations materials and content; coordination of capital
markets outreach with key members of the professional investment
community; development of retail broker relations; providing market
feedback from investors and coordination of basic media relations.
Under the terms of the agreement, DiaMedica will pay Equicom a
monthly retainer fee of $5,000 for select strategic investor
relations and communication services. The initial contract term is
12 months and is effective June 2, 2009.
About DiaMedica
DiaMedica is focused on developing novel treatments for type 2
diabetes based on a newly discovered 'nerve reflex' mechanism for
which the Company has been issued two U.S. patents. DiaMedica has
completed a phase IIa clinical trial with DM-71 which demonstrated
the ability to reduce HbA1c (blood sugar) levels and weight in
humans. DiaMedica also completed a phase IIa trial with its second
compound, DM-83, designed to measure changes in insulin and
glucose. The Company's third drug in clinical development, DM-99,
completed a phase IIa trial in Q1 2009. Encouraging results from
this exploratory clinical study displayed a positive trend in blood
glucose in type 2 diabetes patients after they consumed a meal.
Earlier preclinical results from Vanderbilt University indicated
that DM-99 is able to cause tissue to increase its uptake of sugar
from the blood by over 40% (p less than 0.001) during the first 60
minutes of treatment. The Company is also working on DM-199, a 40x
more biologically active version of DM-99, along with other early
stage development programs. DiaMedica has been recognized as one of
the Top Ten(TM) Life Science companies in Canada for the past two
years by the Ottawa Center for Research and Innovation.
About Equicom Group
Equicom, a wholly-owned subsidiary of TMX Group Inc., is a
leading Canadian provider of investor relations and strategic
corporate communications services. With proven expertise in
developing and executing highly effective strategic communications
programs, and an extensive network of investment community
contacts, Equicom specializes in helping clients achieve their
capital markets objectives. Equicom offers a comprehensive suite of
services including: investor relations, media relations, annual
report production, multimedia and web design, web casting, live
event management and corporate branding. Equicom is headquartered
in Toronto, with offices in Montreal and Calgary. For further
information, please visit www.equicomgroup.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable
Canadian provincial securities legislation (collectively,
"forward-looking statements"). These forward-looking statements
relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook,
including, without limitation, our anticipated future operating
results, and can, in some cases, be identified by the use of words
such as "believe," "anticipate," "expect," "intend," "plan,"
"will," "may" and other similar expressions. In addition, any
statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements.
These statements reflect management's current beliefs and are
based on information currently available to management. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
DiaMedica's early stage of development, lack of product revenues
and history of operating losses, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters,
management of growth, partnerships for development and
commercialization of technology, effects of insurers' willingness
to pay for products, system failures, dependence on key personnel,
foreign currency risk, risks related to regulatory matters and
risks related to intellectual property and other risks detailed
from time to time in DiaMedica's filings with Canadian securities
regulatory authorities, as well as DiaMedica's ability to
anticipate and manage the risks associated with the foregoing.
Additional information about these factors and about the material
factors or assumptions underlying such forward-looking statements
may be found in the body of this news release, as well as under the
heading "Risk Factors" contained in DiaMedica's final long-form
prospectus dated March 12, 2007. DiaMedica cautions that the
foregoing list of important factors that may affect future results
is not exhaustive. When relying on DiaMedica's forward-looking
statements to make decisions with respect to DiaMedica, investors
and others should carefully consider the foregoing factors and
other uncertainties and potential events.
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, DiaMedica cannot provide
assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to
update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: DiaMedica Inc. Kevin Richardson, Ph.D. 204.478.5605
204.453.3745 (FAX) krichardson@diamedica.com www.diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024